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HIV controllers (HCs) are individuals who can naturally control HIV
infection, partially due to potent HIV-specific CD8+ T cell re-
sponses. Here, we examined the hypothesis that superior function
of CD8+ T cells from HCs is encoded by their T cell receptors (TCRs).
We compared the functional properties of immunodominant HIV-
specific TCRs obtained from HLA-B*2705 HCs and chronic progres-
sors (CPs) following expression in primary T cells. T cells trans-
duced with TCRs from HCs and CPs showed equivalent induction
of epitope-specific cytotoxicity, cytokine secretion, and antigen-
binding properties. Transduced T cells comparably, albeit mod-
estly, also suppressed HIV infection in vitro and in humanized
mice. We also performed extensive molecular dynamics simula-
tions that provided a structural basis for similarities in cytotoxicity
and epitope cross-reactivity. These results demonstrate that the
differential abilities of HIV-specific CD8+ T cells from HCs and
CPs are not genetically encoded in the TCRs alone and must de-
pend on additional factors.
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HIV infection persists despite the induction of humoral andcell-mediated host immune responses. In most patients,
known as chronic progressors (CPs), HIV infection leads to
progressive depletion of CD4+ T cells and resultant severe im-
mune deficiency if not treated with combination antiretroviral
therapy (cART). HIV-specific immunity in these patients re-
duces viremia transiently but fails to suppress it durably (1, 2). In
contrast, HIV controllers (HCs) durably maintain viral loads of
less than 2,000 RNA copies per milliliter of plasma without
cART (1, 2). HIV-specific CD8+ T lymphocyte (CTL) responses
play a dominant role in controlling viremia in HCs (3–6). During
acute infection, CTL responses exert antiviral pressure, the
magnitude of which correlates with the viral set point (7). These
responses likely lead to enhanced immunologic control in HCs,
because HIV-specific CTLs from HCs are functionally superior
to those from CPs (4, 6, 8, 9). CTLs from HCs mediate more
efficient HIV inhibition in vitro (10–12), polyfunctional secretion
of cytokines such as IL-2 and IFN-γ (1, 10, 11), greater antigen-
induced proliferation (10, 13), less T cell activation (4), and
evasion of regulatory T cell suppression (14). CTLs from HCs
may also be phenotypically more inclined to protect from HIV
infection for long durations (9, 15) and sustain effector functions
without T cell exhaustion (16). Several HLA-I alleles, including
B*2705 and B*5701, are enriched in HCs (17, 18), underscoring
the role of CTLs in suppressing HIV infection. However, these
alleles are neither necessary nor sufficient to confer protection
against HIV disease progression (6).
Direct comparison of HIV-specific CTLs isolated from HCs
and CPs may elucidate the factors underlying protection. In
HLA-B*2705+ individuals, the HIV-specific CTL responses are
largely focused on the KK10 (KRWIILGLNK) epitope in the
Gag protein (19) and are often dominated by one or two clono-
types, each with a unique T cell receptor (TCR) (8, 12). B27-
KK10–specific CTL clonotypes from HCs and CPs were previously
shown to diverge in their in vitro functional capabilities (8). The
CTL repertoire in HCs was comprised of immunodominant ef-
fective clones and subdominant ineffective clones, whereas in CPs
both immunodominant and subdominant clones were ineffective
at controlling HIV in vitro (8). Therefore, we hypothesized that
the TCR, the sole genetic difference between CTL clones within
a patient and the sole determinant of antigen specificity, might
determine whether a particular CTL clone effectively controls
HIV. The avidity and cross-reactivity of a T cell are also func-
tions of its TCR, and these characteristics influence the effec-
tiveness of antiviral immunity (20). In particular, high-avidity
B27-KK10–restricted CTLs were shown to be associated with
viral control (21). While high functional avidity or antigen sen-
sitivity can correlate with superior T cell function, it can also
correlate with heightened senescence or turnover (22). Existence
of high-avidity public TCR clonotypes in HCs suggests a TCR-
dependent mechanism of viral control (23). Molecular dynamics
(MD) simulations of both effective and ineffective clonotypes
derived from a single patient suggest that inherent sequential,
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structural, and dynamical differences between TCRs provide a
basis for differences in CTL activity (24). Moreover, superior
immunodominant HIV-specific TCRs from CD4+ T cells are
also associated with viral control (25). Thus, there is evidence to
suggest that immunologic control of HIV may be a function of
the TCRs that mediate HIV-specific immunity (26). A recent
report based on data from a single HC indicated that clonotype-
specific differences between CTLs are not dependent on their
TCRs alone (27). However, those results do not address the role
of TCRs in HIV control because they did not compare TCRs
from HCs and CPs. To elucidate the role of TCRs in HIV
control, a direct comparison of TCRs from individuals with dif-
ferent virologic and immunologic status is required. Therefore,
in this study, we addressed this question directly by comparing
the functional characteristics of B27-KK10–specific TCRs from
three types of patients: HCs who maintained low levels of vire-
mia stably, CPs who progressed to high viral loads, and failed
controllers (FCs) who suppressed viremia initially but progressed
to high viral loads. We isolated immunodominant TCRs from
two patients from each group and tested their function in vitro
and in vivo. Furthermore, we applied MD simulations to in-
vestigate the structural and dynamical features of bound pHLA–
TCR complexes. Through these studies, we addressed whether
differential function of HIV-specific CTLs in patients with di-
verse immunologic outcomes is genetically encoded in their TCRs.
Results
Cloning and Expression of Immunodominant B27-KK10–Specific TCRs.
We sorted B27-KK10-dextramer (hereafter called dextramer)-
labeled CD8+ T cells from peripheral blood of two B*2705+
patients from each of the following groups—HCs, FCs, and CPs—
and isolated TCRs from them (Table S1). A unique immu-
nodominant TCR was identified from each patient based on
its frequency in the total B27-KK10–specific CTL repertoire.
These TCRs showed diverse usage of Vα and Vβ families and
CDR3 regions as demonstrated in Table S2. We coexpressed
these TCRs with a reporter gene (LNGFR) in activated primary
human T cells and measured transduction and surface expres-
sion by flow cytometry (Fig. S1 A–C). Despite similar levels of
transduction, a range of surface expression as measured by B27-
KK10-dextramer staining was observed, presumably due to their
differential competitive strengths relative to endogenous TCRs
expressed by T cells. To account for this heterogeneity, we di-
luted TCR-transduced cells with mock-transduced cells to nor-
malize the total number of dextramer+ cells in the effector cell
population for each TCR. As a control, we used F5, a TCR that
recognizes the HLA-A2–MART1 epitope (28).
HIV-Specific TCRs from HCs, FCs, or CPs Respond to Cognate Antigens
Equally Well. We measured the ability of TCRs to induce cyto-
toxicity upon recognition of antigen-presenting target cells. To
that end, we coincubated TCR-transduced effector T cells with
B27-KK10–expressing target cells and counted surviving target
cells at 24 h by flow cytometry (Fig. S2A). We used two different
types of target cells for these assays: (i) GXR-B27+ cells pulsed
with KK10 peptide to provide overexpressed HLA and a short
pulse of antigen stimulation (Fig. 1A) and (ii) autologous HLA-
B27+ primary T cells pulsed with KK10 peptide for physiological
levels of HLA expression and a short pulse of antigen stimula-
tion (Fig. 1B). All B27-KK10–specific TCRs induced cytotoxicity
in an antigen-specific manner, as evidenced by lack of cytotox-
icity induced either by effector cells transduced with F5 TCR
(Fig. 1 A and B) or by target cells pulsed with KY9, a B27-
restricted epitope from HIV (Fig. S2B). We confirmed that
the transduced cells were loaded equally well with Perforin,
irrespective of the transduced TCR, and thus the measured
cytotoxicity output was a result of degranulation caused by TCR–
peptide–HLA interactions (Fig. S1 E and F). Surprisingly, we
observed that the cytotoxic abilities of HC–, FC–, and CP–TCRs
were equivalent in both contexts of antigen presentation. To
assess whether interference from or mispairing with the endogenous
TCR affects cytotoxicity, we constructed variants of these TCRs
with murine constant regions. Despite higher surface expression
and presumably diminished mispairing in the modified TCRs, the
functional equivalence between HC– and CP–TCRs remained
intact (Fig. S3). We used the unmodified TCRs for subsequent
testing to avoid influence of murine constant regions on their
antigen-binding properties.
To test whether these TCRs can induce antigen-specific cy-
totoxicity toward cells infected with HIV (strain NL4-3), we used
GXR-B27+ cells, which express GFP upon infection, as targets.
HC–, FC–, and CP–TCRs induced equivalent specific killing of
infected cells (Fig. 1C) and did not affect uninfected cells (Fig.
S2C). Moreover, this effect was dependent on presentation of
the wild-type KK10 epitope, as demonstrated by diminished cy-
totoxicity toward cells infected with NL4-3 encoding a known
escape mutant R2T (KTWIILGLNK) (Fig. S4). We also tested if
these TCRs induced suppression of HIV in autologous cocul-
tures with HIV-infected HLA-B27+ primary T cells by measur-
ing p24 antigen levels in culture supernatant. HC–, FC–, or
CP–TCRs induced similar levels of viral suppression (Fig. 1D).
These results indicate that TCRs from all three groups were
equally capable of inducing a cytotoxic antiviral response upon
recognition of their cognate antigen, in contrast to our previously
published observations using bulk CTLs or CTL clones from
HCs and CPs (8). However, the ability of transduced T cells to
inhibit viral replication was significantly lower than our previous
results with the parent CTL clones and in some cases not sig-
nificantly different from the controls. While this may be due to
differences in the assay setup, it may also be due to the trans-
duced cells being less efficient at inhibiting viral replication
compared with the original CTL clones. However, the observa-
tion that TCRs from patients with distinct immunologic out-
comes were similar is consistent with the rest of the results.
Another dimension of the CTL response is the ability to produce
effector cytokines upon antigen recognition. We first measured
IFNγ secretion induced by B27-KK10–specific TCRs upon an-
tigenic stimulation. In agreement with the cytotoxicity results,
Fig. 1. B27-KK10–specific TCRs from HCs, FCs, and CPs induce equivalent antigen-
specific responses. (A) GXR-B27+ cells pulsed with KK10 peptide used as
target cells. An effector:target (E:T) ratio of 2:1 is indicated by dark bars and E:
T ratio 4:1 indicated by light bars. Bars represent mean ± SD from n = 6. (B)
Autologous B27+ cells pulsed with KK10 peptide used as targets. Bars repre-
sent mean ± SD of n = 3. (C) HIV-infected GXR-B27+ cells used as targets.
Cytotoxicity at 24 h postcoincubation is shown. E:T ratio of 8:1 indicated by
dark bars, and E:T ratio of 4:1 indicated by light bars. Bars represent mean± SD
from n = 3. (D) Reduction in HIV infection in autologous cocultures by T cells
transduced with HC–, FC–, and CP–TCRs at 6 d in culture. Bars represent mean ±
SD from n = 3.
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relative IFNγ secretion among the TCRs was similar when using
peptide-pulsed GXR-B27+ cells (Fig. 2A) or peptide-pulsed
(Fig. 2B) or HIV-infected (Fig. 2C) autologous HLA-B27+
T cells as target cells. Furthermore, we measured the ability of
TCRs to induce secretion of 13 effector cytokines upon stimu-
lation with peptide-pulsed autologous HLA-B27+ T cells as
targets. B27-KK10–restricted TCRs stimulated detectable se-
cretion of IL-4, IL-17A, TNFα, sFasL, Granzyme A, Granzyme
B, and Perforin (Fig. 2D and Fig. S5). However, all three groups
of TCRs induced similar levels of these cytokines, reinforcing the
functional equivalence of these TCRs.
Antigen-Binding Characteristics of B27-KK10–Specific TCRs. Func-
tional avidity, antigen sensitivity, and cross-reactivity are prop-
erties that often distinguish effective and ineffective T cells. We
first compared the functional avidity of TCRs by measuring in-
tracellular IFNγ production in transduced cells upon stimulation
with a range of concentrations of KK10 peptide in autologous
assays (Fig. 2E). The observed functional avidities of all six TCRs
were within 17–60 nM, which is within the expected range for T
cell clones (8, 29). Importantly, all three groups of TCRs showed
similar functional avidity, highlighting their functional equiva-
lence (Fig. 2E and Fig. S6 A and B). Similar results were also
obtained by measuring cytotoxicity upon stimulation with a range
of peptide concentrations (Fig. S6C) and by measuring antigen
sensitivity by dextramer staining (Fig. S6 D–G). We also com-
pared the cross-reactivity of these TCRs toward 17 documented
escape mutants of the KK10 epitope. We measured cytotoxicity
and IFNγ secretion induced by TCRs upon recognition of GXR-
B27+ cells pulsed with mutant peptides. All of the TCRs showed
unique but overlapping profiles of variant recognition. Gener-
ally, multiple mutations in the KK10 epitope were not as well
tolerated as single mutations. The mutants R2T and R2KL6M
were not well-recognized, whereas L6M and R2Q were recog-
nized almost as efficiently as the wild-type peptide (30). Im-
portantly, there was no remarkable global difference between
HC– and CP–TCRs (Fig. 2F). These results indicate that the
antigen-binding characteristics of the three groups of TCRs
were equivalent.
In Vivo Control of HIV by HC– and CP–TCRs.We investigated whether
the functional equivalence of HC– and CP–TCRs extends to
their ability to control HIV infection in human peripheral blood
mononuclear cell (huPBMC) mice as described in Fig. S7A. We
generated huPBMC mice engrafted with HLA-B27+ primary
T cells transduced with HC– or CP–TCRs, challenged the mice
intraperitoneally with NL4-3, and monitored the frequency of
CD4+ T cells for 4 wk. As expected, mice engrafted with F5 or
mock-transduced T cells showed depletion of CD4+ T cells upon
challenge compared with unchallenged mice. Mice receiving
T cells transduced with B27-KK10–specific TCRs prevented
CD4+ T cell depletion significantly at 3–4 wk postchallenge. In
agreement with in vitro results, HC– and CP–TCRs were in-
distinguishable in their ability to prevent CD4+ T cell depletion
in vivo (Fig. 3A and Fig. S7). We performed viral load mea-
surements in a subset of challenged mice. Mice receiving HC25-
or CP27-transduced T cells had lower viral loads than controls
(Fig. 3B). HC25 and CP27 showed comparable ability to sup-
press viremia in vivo. Taken together, our results indicate that
immunodominant B27-KK10–specific TCRs from HCs and CPs
were functionally equivalent in vitro and in vivo.
Structure and Dynamics of HLA-B27–KK10–TCR Complexes for HC–,
FC–, and CP–TCRs. Seeking a physical explanation for the ob-
served functional equivalence among the TCRs under in-
vestigation, we next conducted extensive MD simulations of
HLA-B27–KK10–TCR structures (pHLA–TCR). These MD
simulations describe both the structure and dynamics at the
pHLA–TCR interface with atomistic details, sampling the
dominant HLA–KK10 and TCR–KK10 interactions that are
most likely to correspond with immunological function. Fur-
thermore, free energy perturbation (FEP) calculations are used
to assess the effects of peptide and protein mutations in silico.
Standard MD trajectories should thus provide insight into the
binding properties of wild-type KK10 complexes, while FEP
calculations can help deliver mechanistic explanations of muta-
tional escape (22). In general, each pHLA–TCR complex
is configured with the KK10 peptide bound inside the
HLA-B*27:01 binding groove and with each TCR bound to the
still-exposed portion of KK10 (Fig. S8A). As no TCR crystal
structures were available for reference, we constructed homology
models for each TCR sequence using high-identity crystal tem-
plates, aligned these models with B*27:01–KK10 configurations
derived from available ternary (B*27:01–KK10–TCR) crystal
structures (31), and subjected resulting complexes to optimiza-
tion with long (1 μs-long) MD trajectories (Table S3). As high-
lighted in Fig. 4A, we observed that HC27, CP27, and FC5.5 engaged
with diverse epitopes consisting of the central, N-, and C-terminal
residues of KK10, often with significant (>10 kcal/mol) per-residue
Fig. 2. B27-KK10–specific TCRs from HCs, FCs, and CPs show similar in-
duction of cytokine secretion and antigen-binding properties. (A and B)
Cytokine secretion by T cells transduced with B27-KK10–specific TCRs at 24 h
after incubation with target cells expressing their cognate antigen. (A) GXR-
B27+ cells pulsed with KK10 peptide as target cells. Bars represent mean ±
SD from n = 3. (B) Autologous B27+ cells pulsed with KK10 peptide used as
target cells. Bars represent mean ± SD from n = 3. (C) Autologous B27+ cells
infected with HIV used as target cells. Cytokine secretion was measured at
7 d postcoincubation. Bars represent mean ± SD from n = 6 from two in-
dependent experiments. (D) Cytokine secretion by transduced T cells at 24 h
after coculture with autologous B27+ target cells pulsed with KK10 peptide.
The heatmap indicates relative values of each cytokine quantified as pg/mL
secreted per LNGFR+dextramer+ cell. Mean data from five serial dilutions
from n = 1 shown. (E) Measurement of functional avidity by staining for
intracellular IFNγ-producing cells upon 6 h of stimulation with GXR-B27+
cells pulsed with reducing doses of KK10 peptide (102–10−8 μg/mL). Data
points represent mean ± SD of n = 4. The lines represent curves fitted by
least squares fit. The dotted line indicates 50% response. (F) Cross-reactivity
of TCRs to variants of the KK10 peptide as measured by percentage sur-
vival of target cells at 24 h after coincubation. The key indicates percentage
survival of target cells relative tomock-transduced T cells. Data represent mean
of n = 3. Statistical comparison was done using ANOVA followed by univariate
analysis. There was no statistical difference between groups of TCRs.
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interaction energies; CP7.9 interacted primarily with the center and
C terminus of KK10, and HC25 promoted only weak interactions
with the center of the presented peptide. While epitope character-
istics vary within each of the TCRs, no clear distinction emerged
among the HC–, FC–, and CP–TCRs. All of the TCRs displayed a
broad composition of residue types at the pHLA–TCR interface.
HC27, FC5.5, and CP27 presented charged or acidic residues that
interact strongly with K1 of KK10, whereas HC25 and CP7.9
presented mostly hydrophobic residues that interact weakly at
that position. All five TCRs exhibited a mixture of hydrophobic
and polar residues near the middle of KK10, supporting com-
mon epitope contributions from the hydrophobic ILGL “core”
of KK10 (KRWIILGLNK). The importance of these central
hydrophobic residues to TCR binding was established in our previous
study of HC FW56, wherein the binding characteristics of TCRs
could be distinguished via the KK10 hydrophobic core alone (24).
Here, direct comparison among clonotypes is complicated by the fact
that TCR sequences are drawn from separate patients, resulting in
some additional differences in terminal binding characteristics.
Nevertheless, we see that the “ILGL” core also plays a significant
and common role in the binding of the five TCRs studied here.
We also calculated the interaction energies and solvent-
accessible surface areas (SASAs) in the ternary complexes (Fig.
4B). From a physical perspective, low interaction energies (i.e.,
related to strong binding) and low peptide SASAs (i.e., related
to deep burial) should generally correspond to good recogni-
tion (32, 33). Overall, the interaction energy and SASA calcu-
lations revealed no clear distinction among the TCRs in KK10-
restricted interactions at the molecular level. We next modeled
TCR cross-reactivity in pHLA–TCR ternary complexes using FEP
to quantitatively estimate the binding affinity changes result-
ing from KK10 mutations. Specifically, we computed binding
free energy differences between the wild-type KK10 and five
mutants, including both single- and double-point mutations
(Fig. 4C). A reasonable statistical correlation (R2 = 0.33) was
observed between binding ΔΔG values and raw cytotoxicity
values from HC–, FC–, and CP–TCRs (Fig. S8B). Specifically,
the well-recognized L6M mutant resulted in mild changes in
binding affinities of pHLA–TCR complexes. Notably, Ladell
et al. (31) reported a unique role for the TRBV6-5 TRBJ1-1
TCR motif in controlling the L6M escape mutation. This CDR3β
motif is not found in any of the five TCRs studied here, sug-
gesting these TCRs independently evolved robustness to L6M-
related escape (see SI Methods for further discussion). Among
single mutations at KK102, R2Q induced the least dramatic
change, on average; R2K and, particularly, R2T yielded higher
ΔΔG values. All of the above observations relate well to the
functional data (Fig. 2F). The double mutations generally led to
even larger binding free energy changes, in agreement with the
heightened escape observed in vitro. Mutations at KK102 gener-
ally led to diminished HLA interactions as well (Fig. 4 C–E),
with the exception of those involving R2K. We did observe two
subtly distinct mechanisms for the escape of R2KL6M: In the
HC27 complex, mutations pulled the N-terminal residues KK101–4
outward, whereas in the CP7.9 complex, mutations pulled residues
5, 7, and 8 outward. In both cases, KK10–TCR binding was di-
minished. Overall, these in silico mutagenesis results correlate
well with the cross-reactivity data for HC–, FC–, and CP–TCRs.
Considered in concert, our structural modeling supports the no-
tion that these TCRs cannot be differentiated with respect to
recognizing the KK10 peptide and preventing mutational escape.
Fig. 4. MD simulations of pHLA–TCR structures. (A) Epitope configurations
cultivated by various TCRs. Conformations were drawn from high population
clusters of MD trajectory data, and energy calculations are restricted to peptide–
TCR interactions. For visual clarity, KK10 is represented from the C terminus to
N terminus, and interfacial TCR residue types are colored according to the
following key: white, hydrophobic; green, polar; red, acidic; blue, basic. For
clarity, the presenting HLA molecule (B*27:01) is not rendered but would ap-
pear above KK10 in each complex. (B) Global observables (restricted energy
and SASA) for epitopic interactions. Error bars represent SDs observed in MD
simulations. HC and FC data are presented in blue, while CP data are shown in
red. (C) Binding free energy changes of KK10 mutants to HC–, FC–, and CP–
TCRs. ΔΔG values were calculated using alchemical FEP cycles. Data specific
to TCRs used the KK10-B*27:01 complex as a free state reference, while values
related to the HLA invoked isolated KK10 as the free state. (D) Schematic
representation of ternary complex featuring residues prone to mutational
escape (R2 and L6). (E) Effect of KK10-2 mutations on peptide–HLA interac-
tions. Energy calculations involve only KK102 and E45 of B*27:01. (F) Divergent
escape mechanisms for HC27 and CP7.9 specific to KK10-R2KL6M. Mutated
KK10 residues (and their WT correspondents) are rendered in orange, and
interfacial TCR residues are colored according to the previously mentioned key.
ΔE values were computed from energies restricted to KK10–TCR interactions.
Fig. 3. Ability of T cells transduced with HC– and CP–TCRs to suppress HIV
infection in vivo. (A) Frequency of CD4+ T cells in mice over 4 wk post-
challenge with HIV. Data points show mean ± SD from two independent
experiments. The number of mice in each arm was as follows: HC25 = 10,
HC27 = 11, CP27 = 17, CP7.9 = 10, F5 = 9, mock = 12, unchallenged = 18.
Asterisk indicates a statistically significant difference in %CD4+ cells at week
4 postchallenge compared with “mock” using unpaired t tests. The variances
are not significantly different as per F test. (B) Viral loads in plasma of in-
dividual mice receiving transduced cells at 2–4 wk postchallenge with HIV.
Data points indicate individual mice from one experiment.
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Discussion
HCs demonstrate that CD8+ CTLs, under the right conditions,
can control HIV infection durably. In contrast, FCs and CPs
demonstrate that this ability of CTLs can be limited, leading to
failed immunologic control. Here we investigated if clonotype-
associated functional differences between B27-KK10–specific
CTLs from HCs and CPs are explained by inherent properties of
the TCRs derived from them. Surprisingly, TCRs from HCs,
FCs, and CPs showed equivalent abilities to induce antigen-
specific cytotoxicity, secrete effector cytokines, and suppress
HIV infection in vivo and in vitro. Moreover, the antigen-binding
characteristics of the TCRs, namely functional avidity and cross-
reactivity, were indistinguishable. Therefore, our results suggest
that differences in CTL responses in HCs and CPs were not due
to differences in functional properties of their TCRs. While our
results extend considerably the studies recently reported by
Flerin et al. (27), they contrast with previous data showing di-
vergent function in CTL clones from one HC (CTR203) and two
CPs (CR338 and FEN33), from which TCRs HC25, CP27, and
CP7.9 tested here were derived (8). Unfortunately, the original
CTL clones are no longer viable, preventing their direct com-
parison with transduced T cells in our assays. Our results show
that superior CTL function is not explained by superior TCRs and
is likely due to some other aspect of the CTL clones. CTL clones
could likely reflect the immunological status of the cells from
which they were derived and hence could retain their epigenetic
characteristics. In the current study, the use of transduced acti-
vated T cells from healthy donors in functional assays ensures an
epigenetically equivalent background for comparing TCRs.
There are a number of caveats that should be considered in
evaluating these data. First, the number of patients from which
TCRs were derived was small. However, the result that six TCRs
from six different patients were functionally similar is compel-
ling, especially given the diversity of the Vα and Vβ families and
CDR3 regions among the TCRs. Second, as expected, the ex-
pression level of the individual TCRs in primary T cells varied,
despite similar levels of transduction. Although this may have
influenced functional characteristics, the magnitude of these
differences was small and unlikely to mask differences in TCR
function. Whether the use of dextramers to capture immunodo-
minant clonotypes may have favored more functional TCRs is also
a consideration. Finally, the levels of cytotoxicity and inhibition of
replication were much lower than that observed with the parent
cells, but unfortunately, the original cells were not available for
direct comparison. Despite these caveats, the overall findings
strongly indicate functional equivalence of these TCRs.
To address whether structural resemblance plays a role in
functional similarity, we performed MD simulations that revealed
diverse modes of pHLA–TCR interactions unique to each TCR.
Despite diverse residues involved in the interactions, the overall
structures predicted similar function, in agreement with our experi-
mental findings. Our previous results reported in Xia et al. (24)
showed that structural differences among distinct B27-KK10–specific
clones within one patient correlated with functional differences,
with results generated in blinded fashion, indicating the ability
of the MD simulations to predict functional differences. In the
current study, however, the lack of overall structural differences
between HC– and CP–TCRs seems to support their functional
similarity. The FEP perturbation studies agreed well with in vitro
data and were able to predict cross-reactivity of TCRs to the tested
mutant epitopes. Taken together, they further support the notion
that HC– and CP–TCRs can be equally susceptible to mutational
escape of KK10.
Overall, our observations imply that the lack of viral control
exhibited by CPs and FCs must be due to loss of their functional
capabilities. Although the data shown here are limited to TCRs
recognizing the KK10 epitope, it will be interesting to see if they
generalize to other epitopes in HIV. In the one HC and two CPs,
from whom viral sequence could be obtained, the predominant
species of virus bears the wild-type KK10 epitope, precluding
mutational escape as the reason for lack of control. Therefore,
our data predict that an effective CTL response, while essential,
may be insufficient to provide immune control. We postulate
that other factors may be acting in concert with CD8+ CTLs to
allow HCs to exert greater control over viral replication, prevent
exhaustion, and preserve immune function, independent of their
TCRs. These factors could involve the innate immunity to the
virus (2), fitness of the virus during hyperacute infection (34),
NK cell activity associated with protective HLA alleles (35, 36),
and cytokine production during acute and chronic phases of
infection (37, 38). To address these factors in a TCR-specific
manner, experimental systems that allow differentiation of
CTLs bearing a particular TCR in an antigen-naïve environment
are needed. We are currently investigating if humanized mice
engrafted with hematopoietic stem/progenitor cells expressing
HC– or CP–TCRs can be used to address these factors. A recent
report showed that an additional facet of HIV-specific CD8+
T cell response in HCs was the recognition of epitopes presented
by class II HLA alleles, which exhibit antiviral activity. It will be
interesting to study the role of TCRs in such activity and whether
it contributes to viral control (39). Our results also show po-
tential for developing immunotherapies to treat HIV infection.
The results showing that TCR gene transfer conferred HIV-
specific cytotoxic activity, ability to recognize epitope variants,
and ability to control HIV infection in vivo are encouraging from
a therapeutic standpoint. These data highlight the potential of
these TCRs for immunotherapy to achieve at least partial control
over HIV infection. We postulate that these TCRs can be used in
either short-term immunotherapy using transduced autologous
primary T cells or as long term-immunotherapy using transduced
autologous hematopoietic stem/progenitor cells in HLA-B27+
patients. These results can also be potentially extended to pa-
tients with other HLA types. We are currently testing the efficacy
of TCR-based immunotherapy approaches to treat HIV in-
fection in humanized mice.
Materials and Methods
In Vitro Functional Assays. To measure in vitro cytotoxicity, primary hu-
man T cells were activated and transduced as described in SI Methods.
Surface expression of the TCRs was checked by flow cytometry, and the
%dextramer+ was normalized to 2% by mixing dextramer+ cells with mock-
transduced cells. In assays using GXR-B27+ cells as targets, they were pulsed
at 1 × 106 cells per milliliter with 100 μg/mL peptide for 2 h at 37 °C. Fol-
lowing the incubation, the cells were washed twice with culture medium
and used immediately for the assay. In the assays using autologous target
cells, T cells were labeled with CFSE (Biolegend) for 15 min at 37 °C, washed
twice with cold PBS, and resuspended at 1 × 106 per milliliter in culture
medium. The cells were then pulsed with 100 μg/mL peptide for 2 h at 37 °C,
washed twice, and used immediately for the assays. To perform the cyto-
toxicity assays, 5 × 104 target cells and the required number of effector cells
were mixed together and plated in 96-well flat-bottom plates and placed in
a humidity chamber. The cells were harvested 24 h later and mixed with half
volume of PBS + 2% FBS with 30 μg/mL propidium iodide (Life Technologies)
and acquired immediately on MACSQuant 10 (Miltenyi). The remaining cells
were centrifuged at 500 g for 5 min at 4 °C, and a fraction of the super-
natant was collected for measurement of IFNγ. The data were analyzed on
Flowjo v10 as described in Fig. S2. To measure functional avidity, GXR-B27+
cells were incubated with 102–10−8 μg/mL peptide for 2 h at 37 °C, followed
by coincubation with transduced T cells in the presence of Brefeldin A
(Biolegend) for 6 h. Cells were first stained for LNGFR expression, fixed and
permeabilized, and then stained for intracellular IFNγ production (see SI
Methods for detailed procedures). Each assay was performed using three to
four technical replicates, and each assay was repeated independently three
to six times. All of the peptides used in coculture experiments were syn-
thesized from Pierce ThermoFisher. To measure antigen sensitivity, TCR-
transduced Jurkat cells were stained with B27-KK10-tetramer and anti-TCRαβ
antibody, gated on a narrow range of TCR expression to measure dextramer
staining intensity (see SI Methods for detailed procedures). TCR-induced secre-
tion of IFNγ was measured using an ELISA kit (Life Technologies/eBiosciences)
according to the manufacturer’s protocol. For multiplexed measurement of
cytokines, LEGENDPlex human CD8/NK kit (Biolegend) was used according to
the manufacturer’s instructions. The samples were acquired on Macs-
quant 10 and analyzed on the LEGENDPlex analysis software.
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In Vitro HIV Suppression Assay. Primary human T cells from an HLA-B27+ donor
were activated and transduced as described in SI Methods. To prepare target
cells, autologous PBMCs were incubated with 0.5–1 μg p24 of NL4-3 at 1 × 106
cells per milliliter for 4 h at 37 °C in culture medium supplemented with
0.5 μg/mL anti-CD3:8 bispecific antibody [obtained from Johnson Wong and
Galit Alter through the NIH AIDS Reagent Program, Division of AIDS, National
Institute of Allergy and Infectious Diseases (NIAID), NIH]. The cells were
washed and resuspended in culture medium supplemented with 40 U/mL
IL-2 and anti-CD3:CD8 antibody for 7 d. At day 7, the cells were harvested,
counted, and plated at 5 × 104 cells per well in a flat-bottom 96-well plate.
TCR-transduced cells were incubated with target cells at various Effector:
Target ratios in a final volume of 200 μL per well. The culture supernatant was
collected 7 d later, and the viral load was determined by measuring
p24 antigen by ELISA (Zeptometrix) according to the manufacturer’s protocol.
HomologyModeling. ToenableMDsimulationsof the five TCR clonotypes studied
in this work, homologymodelswere constructed for each of the TCR sequences of
interest using the MODELER 9.17 software package. In brief, target sequences
were aligned with candidate templates using a standard algorithm; template
structures were then selected on the basis of maximal sequence identity with
constraintson crystal structure resolution, R-free values, andoutlier statistics (Table
S3). The 3D models were then constructed using single templates, selecting the
best of 10 output configurations as determined by discrete optimized protein
energy minimization scores. Specific template information and specific methods
used for MD simulations and FEP calculations can be found in SI Methods.
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